Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism

Ke Ma,a,b @ Yu Feng,a,b,c Alan McNally,d @ Zhiyong Zongb,c,e

a Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China
b Division of Infectious Diseases, State Key Laboratory of Biotherapy, Chengdu, Sichuan, China
c Center for Pathogen Research, West China Hospital, Sichuan University, Chengdu, Sichuan, China
d Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
e Department of Infection Control, West China Hospital, Sichuan University, Chengdu, Sichuan, China

ABSTRACT Aztreonam-avibactam is a promising antimicrobial combination against multidrug-resistant organisms, such as carbapenemase-producing Enterobacteria. Resistance to aztreonam-avibactam has been found, but the resistance mechanism remains poorly studied. We recovered three Escherichia coli isolates of an almost identical genome but exhibiting varied aztreonam-avibactam resistance. The isolates carried a cephalosporinase gene, blaCMY-42, on IncI plasmids with a single-nucleotide variation in an antisense RNA-encoding gene, inc, of the replicon. The isolates also had four extra amino acids (YRIK) in penicillin-binding protein 3 (PBP3) due to a duplication of a 12-nucleotide (TATCGAATTAAC) stretch in pbp3. By cloning and plasmid-curing experiments, we found that elevated CMY-42 cephalosporinase production or amino acid insertions in PBP3 alone mediated slightly reduced susceptibility to aztreonam-avibactam, but their combination conferred aztreonam-avibactam resistance. We show that the elevated CMY-42 production results from increased plasmid copy numbers due to mutations in inc. We also verified the findings using in vitro mutation assays, in which aztreonam-avibactam-resistant mutants also had mutations in inc and elevated CMY-42 production compared with the parental strain. This choir of target modification, hydrolyzing enzyme, and plasmid expression represents a novel, coordinated, complex antimicrobial resistance mechanism and also reflects the struggle of bacteria to survive under selection pressure imposed by antimicrobial agents.

IMPORTANCE Carbapenemase-producing Enterobacteria (CPE) is a serious global challenge with limited therapeutic options. Aztreonam-avibactam is a promising antimicrobial combination with activity against CPE producing serine-based carbapenemases and metallo-β-lactamases and has the potential to be a major option for combatting CPE. Aztreonam-avibactam resistance has been found, but resistance mechanisms remain largely unknown. Understanding resistance mechanisms is essential for optimizing treatment and developing alternative therapies. Here, we found that either penicillin-binding protein 3 modification or the elevated expression of cephalosporinase CMY-42 due to increased plasmid copy numbers does not confer resistance to aztreonam-avibactam, but their combination does. We demonstrate that increased plasmid copy numbers result from mutations in antisense RNA-encoding inc of the IncI replicon. The findings reveal that antimicrobial resistance may be due to concerted combinatorial effects of target alteration, hydrolyzing enzyme, and plasmid expression and also highlight that resistance to any antimicrobial combination will inevitably emerge.

KEYWORDS aztreonam-avibactam, avibactam, CMY, penicillin-binding protein, plasmid copy number, Escherichia coli, antibiotic resistance, aztreonam
The ongoing rise in the prevalence of multidrug-resistant (MDR) bacterial pathogens has led to a global concerted effort to combat this most serious of global health threats (1). The rise in antimicrobial resistance is an extremely complex and multifactorial problem (2). Studying the mechanisms responsible for resistance to antimicrobial agents of clinical significance in common bacterial pathogens generates critically important insights for combating antimicrobial resistance (1, 3). The Enterobacterales is an order of Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp., that are widely distributed in nature and are major human pathogens, causing infections ranging from intestinal disease and urinary tract infections to invasive bloodstream infections and meningitis (4). Carbapenems such as ertapenem, imipenem, and meropenem are potent antimicrobial agents and the mainstream agents of choice to treat severe infections caused by the Enterobacterales. However, carbapenemase-producing Enterobacterales (CPE) has emerged worldwide, representing a serious challenge for clinical management and public health (5). Carbapenem resistance in Enterobacterales is mainly due to the production of carbapenem-hydrolyzing enzymes (carbapenemases) (6). Carbapenemases can be divided into two major types, i.e., serine-based enzymes with a serine residue in the active site, such as KPC (Klebsiella pneumoniae carbapenemase), and metallo-β-lactamases (MBLs) containing zinc in the active site, such as NDM (New Delhi metallo-β-lactamase) (6, 7).

Avibactam (AVI) is a recently developed non-β-lactam β-lactamase inhibitor with the ability to inhibit serine-based carbapenemases, but it cannot inhibit MBLs (8). The combination of ceftazidime-avibactam (CAZ-AVI) has been in clinical use but has no activity against MBL producers (9). Aztreonam (ATM) is stable to the hydrolysis of MBLs (10, 11), and the combination of aztreonam-avibactam (ATM-AVI) has activity against CPE producing serine-based carbapenemases, MBLs, or both and has the potential to be a major option for combating CPE. Unfortunately, ATM-AVI-resistant strains have been found (12–14), but the resistance mechanisms remain poorly studied. In this study, we report a unique combination of ATM-AVI resistance mechanisms in Escherichia coli.

RESULTS

CMY-42 confers slightly reduced susceptibility to ATM-AVI. E. coli isolates 035123, 035125, and 035148 were recovered from hospital sewage and were resistant to ATM-AVI at different levels (MIC, 16/4, 64/4, and 128/4 mg/liter, respectively) (Table 1; see also Table S1 in the supplemental material). We performed whole-genome sequencing for the three isolates. They belonged to a common strain with only one or two single-nucleotide polymorphisms (SNPs), and all had a 34,321-bp IncI plasmid carrying an AmpC-type cephalosporinase gene, blaCMY-42.

CMY-42 has an amino acid substitution (Ser231Val at Ambler’s position 211) compared to CMY-2 (15). Protein structures of CMY-2 and CMY-42 were predicted (Fig. S1). Molecular modeling of both enzymes showed that compared with CMY-2, CMY-42 has a neonatal polar bond of 2.6 Å present between the hydrogen atom of 231Ser and oxygen atom of 232Ser and has an additional van der Waals force of 2.3 Å among atoms of 231Ser and the spatially adjacent amino acid residues.

To examine whether CMY-42 confers ATM-AVI resistance, we cloned blaCMY-42 onto pET28a to construct pET28a_CMY42, which was introduced into strain BL21. We also cloned blaCMY-2 onto pET28a to construct pET28a_CMY2 as a control. The ATM MIC against BL21::pET28a_CMY42 was 512 mg/liter, 8-fold higher than that for BL21::pET28a_CMY2 (Table 1). It is evident that CMY-42 has significantly stronger activity on ATM than CMY-2. However, the presence of blaCMY-42 only slightly increased the ATM-AVI MIC from 0.015/4 mg/liter for BL21::pET28a to 0.03/4 mg/liter for BL21::pET28a_CMY42, while the presence of blaCMY-2 did not change the ATM-AVI MIC (0.015/4 mg/liter) (Table 1). This suggests that CMY-42 only slightly reduced susceptibility to the combined ATM-AVI. Of note, CMY-42 also confers slightly reduced susceptibility to CAZ-AVI (Table 1 and Table S1).
| Strain and/or plasmid | MIC (mg/liter) of a | Note |
|-----------------------|--------------------|------|
| 035125                | ATM 128 16/4 ATM-AVI 1/8 CAZ 1,024 8/4 CAZ-AVI 0.5/8 | ST410, YRIK insertion in PBP3, carrying \(\text{bla}_{\text{CMY-42}}\) from sewage |
| 035123                | 512 64/4 4/8 >1,024 16/4 1/8 | ST410, YRIK insertion in PBP3, carrying \(\text{bla}_{\text{CMY-42}}\) from sewage |
| 035148                | 512 128/4 16/8 >1,024 32/4 4/8 | ST410, YRIK insertion in PBP3, carrying \(\text{bla}_{\text{CMY-42}}\) from sewage |
| 005008                | >512 4/4 0.5/8 >1,024 64/4 16/8 | ST3835, YRIK insertion in PBP3, carrying \(\text{bla}_{\text{CMY-42}}\) and \(\text{bla}_{\text{NDM-1}}\) from ascites (17) |
| 005008R1              | >512 64/4 4/8 >1,024 256/4 32/8 | ATM-AVI-resistant mutant of 050008, SNP in \(\text{inc}\) |
| 005008R2              | >512 64/4 4/8 >1,024 256/4 32/8 | ATM-AVI-resistant mutant of 050008, SNP in \(\text{inc}\) |
| 020066                | 512 8/4 1/8 >1,024 64/4 16/8 | ST6823, YRIK insertion in PBP3, no \(\text{bla}_{\text{CMY-42}}\), carrying \(\text{bla}_{\text{NDM-1}}\) from urine (22) |
| BL21                  | 0.015 0.015/4 0.015 0.015/4 | \(\text{bla}_{\text{CMY-2}}\) cloned on pET28a |
| BL21:pET28a_CMY2      | 32 0.015/4 32 0.015/4 | \(\text{bla}_{\text{CMY-2}}\) cloned on pET28a |
| BL21:pET28a_CMY42     | 512 0.03/4 >1,024 0.03/4 | \(\text{bla}_{\text{CMY-42}}\) cloned on pET28a |
| 035125ΔpCMY42:pET28a  | 2 1/4 4 1/4 | 035125 without pCMY42, resulting from plasmid curation |
| 035125ΔpCMY42:pET28a_CMY2 | 32 4/4 0.125/8 32 2/4 0.06/8 | \(\text{bla}_{\text{CMY-2}}\) cloned on pET28a |
| 035125ΔpCMY42:pET28a_CMY42 | 512 64/4 2/8 >1,024 32/4 1/8 | \(\text{bla}_{\text{CMY-42}}\) cloned on pET28a |
| 035125ΔpCMY42:pCMY42_035125 | 128 16/4 1/8 1,024 8/4 0.5/8 | pCMY42_035125 introduced back into 035125ΔpCMY42 |
| 035125ΔpCMY42:pCMY42_035123 | 512 32/4 4/8 >1,024 32/4 1/8 | pCMY42_035123 introduced into 035125ΔpCMY42 |
| 035125ΔpCMY42:pCMY42_035148 | 1,024 128/4 16/8 >1,024 32/4 4/8 | pCMY42_035148 introduced into 035125ΔpCMY42 |
| 035125ΔpCMY42:pCMY42_050008 | 128 4/4 0.5/8 1,024 8/4 0.25/8 | pCMY42_050008 introduced into 035125ΔpCMY42 |
| 035125ΔpCMY42:pCMY42_050008R1 | 512 64/4 2/8 >1,024 64/4 1/8 | pCMY42_050008R1 introduced into 035125ΔpCMY42 |
| 035125ΔpCMY42:pCMY42_050008R2 | 512 64/4 2/8 >1,024 64/4 1/8 | pCMY42_050008R2 introduced into 035125ΔpCMY42 |
| BL21::pBC SK          | 0.015 0.015/4 0.015 0.015/4 | \(\text{pbp3}\) of BL21 cloned on pBC SK |
| BL21::pbp3_BL21       | 0.015 0.015/4 0.015 0.015/4 | \(\text{pbp3}\) of BL21 cloned on pBC SK |
| BL21::pbp3_YRIN       | 0.25 0.25/4 0.25 0.25/4 | \(\text{pbp3}\) of 035125 cloned on pBC SK |
| BL21::pbp3_YRIN       | 0.25 0.25/4 0.25 0.25/4 | \(\text{pbp3}\) of 005008 cloned on pBC SK |
| BL21::pbp3_YRIP       | 0.25 0.25/4 0.25 0.25/4 | \(\text{pbp3}\) of 020066 cloned on pBC SK |

*Resistance is highlighted in boldface.*
PBP3 with the insertion of the four extra amino acids confers reduced susceptibility but not resistance to ATM-AVI. The insertion of amino acids in penicillin-binding protein 3 (PBP3), due to duplication of nucleotide sequence, has been found to reduce susceptibility to ATM-AVI (13, 16). All three isolates had a duplication of a 12-nucleotide sequence (TATCGAATAAC) in \( pbp3 \), resulting in four extra amino acids (YRIK) in PBP3 (Fig. 1 and Fig. S2). We cloned \( pbp3 \) of 035125 (\( pbp3_{_YRIK} \)) into BL21 and also cloned \( pbp3 \) of BL21 (\( pbp3_{_BL21} \)) as a control. The MIC of ATM-AVI for BL21::\( pbp3_{_YRIK} \) was 0.25/4 mg/liter, 16-fold the MIC of 0.015/4 mg/liter for BL21::\( pbp3_{_BL21} \) (Table 1). This confirms that the YRIK insertion in PBP3 reduces susceptibility to ATM-AVI but at a level below the resistance breakpoint. However, the recipient strain BL21 has its own \( pbp3 \) gene (\( pbp3_{_BL21} \)), which has no duplication of nucleotide sequence but may blur the effect of \( pbp3_{_YRIK} \). We then cured the \( \text{bla} \) CMY-42-carrying plasmid pCMY42_035125 from 035125 using SDS to remove the additive effect provided by CMY-42. The absence of pCMY42_035125 from 035125ΔpCMY42 was confirmed by PCR. The MIC of ATM and ATM-AVI against 035125ΔpCMY42 was 2 and 1/4 mg/liter (Table 1), respectively. This confirms that the YRIK insertion in PBP3 is unable to confer resistance to ATM-AVI but confers reduced susceptibility. In addition, the YRIK insertion in PBP3 has the same impact on CAZ-AVI (Table 1).

A previous study also reported another type of four-amino-acid insertion, YRIN, in PBP3 of \( E. coli \) (13). We also found such YRIN insertion in PBP3 of \( E. coli \) strain 005008 (17) and detected another type of four-amino-acid insertion, YRIP, in PBP3 of \( E. coli \) strain 020066 (18) in our collections. To examine the impact of the YRIN and YRIP insertions in PBP3, we cloned \( pbp3 \) of 005008 (\( pbp3_{_YRIN} \)) and that of 020066 (\( pbp3_{_YRIP} \)) into BL21. The ATM-AVI MIC for both BL21::\( pbp3_{_YRIN} \) and BL21::\( pbp3_{_YRIP} \) was 0.25/4 mg/liter, the same as that for BL21::\( pbp3_{_YRIK} \) (Table 1). This suggests that insertions of YRIN, YRIK, and YRIP have the same impact on reduced susceptibility to ATM-AVI and CAZ-AVI (Table 1).

The combination of CMY-42 and the insertion of the four extra amino acids of PBP3 confers resistance to ATM-AVI. To examine whether CMY-42 and PBP3 insertion together can confer ATM-AVI resistance, we introduced pET28a_CMY42 into 035125ΔpCMY42 by electroporation and introduced pET28a as a control. The MIC of ATM and ATM-AVI against strain 035125ΔpCMY42::pET28a_CMY42 was 512 and 32/4 mg/liter (Table 1), respectively. In contrast, the MIC of ATM and ATM-AVI against 035125ΔpCMY42::pET28a was 2 and 1/4 mg/liter, respectively. This confirms that \( \text{bla} \) CMY-42 and the PBP3 insertion in combination can confer ATM-AVI resistance. We also introduced pET28a_CMY2 into 035125ΔpCMY42 by electroporation to examine whether \( \text{bla} \) CMY-2 has the same effect as \( \text{bla} \) CMY-42. The MIC of ATM and ATM-AVI against 035125ΔpCMY42::pET28a_CMY2 was 32 and 1/4 mg/liter, respectively (Table 1). This indicates that, unlike \( \text{bla} \) CMY-42, \( \text{bla} \) CMY-2 cannot provide an additive effect to ATM-AVI resistance and to CAZ-AVI resistance (Table 1).

The expression level of \( \text{bla} \) CMY-42 in the presence of the PBP3 amino acid insertion is correlated with the level of ATM-AVI resistance. Compared to pCMY42_035125, there is a single SNP in the 71-bp \( inc \) gene on pCMY42_035123 (G38T) and another on pCMY42_035148 (C30A), the \( \text{bla} \) CMY-42-carrying plasmids of 035123 and 035148 (Fig. 2). To examine the expression of \( \text{bla} \) CMY-42 from the three plasmids, we introduced them into 035125ΔpCMY42 to construct 035125ΔpCMY42::pCMY42_035125, 035123, 035148, 005008, 020066, BL21::pCMY42_035125, and BL21::pCMY42_035123.
We found that bla\textsuperscript{CMY-42} expression in 035125ΔpCMY42::pCMY42\textsubscript{035123} and 035125ΔpCMY42::pCMY42\textsubscript{035148} was increased 2.48- and 11.43-fold, respectively, compared to that of 035125ΔpCMY42::pCMY42\textsubscript{035125} by quantitative reverse transcription-PCR (qRT-PCR). We also determined the transcript level of \textit{repZ}, which reflects the plasmid copy number (19), by qRT-PCR. The transcript levels of \textit{repZ} of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} were increased to 3.48- and 11.86-fold compared to that of pCMY42\textsubscript{035125}, matching the levels observed for \textit{bla}\textsuperscript{CMY-42} (Table 2 and Fig. S3). Correspondingly, the plasmid copy number of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} was 7.00 and 26.81 per chromosome, respectively, and was higher than the value of 2.37 for pCMY42\textsubscript{035125} (Table 2).

Two ATM-AVI-resistant mutants of strain 005008 had an SNP in\textit{inc}. Surprisingly, strain 005008 (17) had \textit{bla}\textsuperscript{CMY-42} and the YRIN insertion in PBP3 but was susceptible to ATM-AVI (MIC, 4/4 mg/liter). To elucidate why, we obtained the complete sequence of 035125, 035125ΔpCMY42::pCMY42\textsubscript{035123}, and 035125ΔpCMY42::pCMY42\textsubscript{035148}. We found that \textit{bla}\textsuperscript{CMY-42} expression in 035125ΔpCMY42::pCMY42\textsubscript{035123} and 035125ΔpCMY42::pCMY42\textsubscript{035148} was increased 2.48- and 11.43-fold, respectively, compared to that of 035125ΔpCMY42::pCMY42\textsubscript{035125} by quantitative reverse transcription-PCR (qRT-PCR). We also determined the transcript level of \textit{repZ}, which reflects the plasmid copy number (19), by qRT-PCR. The transcript levels of \textit{repZ} of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} were increased to 3.48- and 11.86-fold compared to that of pCMY42\textsubscript{035125}, matching the levels observed for \textit{bla}\textsuperscript{CMY-42} (Table 2 and Fig. S3). Correspondingly, the plasmid copy number of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} was 7.00 and 26.81 per chromosome, respectively, and was higher than the value of 2.37 for pCMY42\textsubscript{035125} (Table 2).

Two ATM-AVI-resistant mutants of strain 005008 had an SNP in\textit{inc}. Surprisingly, strain 005008 (17) had \textit{bla}\textsuperscript{CMY-42} and the YRIN insertion in PBP3 but was susceptible to ATM-AVI (MIC, 4/4 mg/liter). To elucidate why, we obtained the complete sequence of 035125, 035125ΔpCMY42::pCMY42\textsubscript{035123}, and 035125ΔpCMY42::pCMY42\textsubscript{035148}. We found that \textit{bla}\textsuperscript{CMY-42} expression in 035125ΔpCMY42::pCMY42\textsubscript{035123} and 035125ΔpCMY42::pCMY42\textsubscript{035148} was increased 2.48- and 11.43-fold, respectively, compared to that of 035125ΔpCMY42::pCMY42\textsubscript{035125} by quantitative reverse transcription-PCR (qRT-PCR). We also determined the transcript level of \textit{repZ}, which reflects the plasmid copy number (19), by qRT-PCR. The transcript levels of \textit{repZ} of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} were increased to 3.48- and 11.86-fold compared to that of pCMY42\textsubscript{035125}, matching the levels observed for \textit{bla}\textsuperscript{CMY-42} (Table 2 and Fig. S3). Correspondingly, the plasmid copy number of pCMY42\textsubscript{035123} and pCMY42\textsubscript{035148} was 7.00 and 26.81 per chromosome, respectively, and was higher than the value of 2.37 for pCMY42\textsubscript{035125} (Table 2).

Two ATM-AVI-resistant mutants of strain 005008 had an SNP in \textit{inc}. Surprisingly, strain 005008 (17) had \textit{bla}\textsuperscript{CMY-42} and the YRIN insertion in PBP3 but was susceptible to ATM-AVI (MIC, 4/4 mg/liter). To elucidate why, we obtained the complete sequence of

![Alignment of the inc gene sequences and predicted RNA folding of Inc antisense RNA stem-loop region.](image)

**FIG 2** Alignments of the inc gene sequences and predicted RNA folding of Inc antisense RNA stem-loop region. (Top) Predicted RNA folding of Inc antisense RNA stem-loop region. The Inc RNA is transcribed from the complementary strand. The mutations are indicated by arrows. The hexanucleotides at the interaction sites with stem-loop 1 within RepZ mRNA are shown by a circle. (Bottom) Alignments of the inc gene sequences. The TTGGCG hexanucleotides, which are important sites for interaction between Inc RNA and stem-loop 1 within RepZ mRNA (23), are highlighted in boldface. The stem-loop region is underlined.

| Strain::plasmid | Expression level (fold ± SD) | Plasmid copy no. |
|-----------------|-----------------------------|------------------|
| 035125ΔpCMY42::pCMY42\textsubscript{035123} | 2.48 ± 0.26 | 7.00 ± 0.66 |
| 035125ΔpCMY42::pCMY42\textsubscript{0351148} | 11.43 ± 2.06 | 26.81 ± 1.91 |
| 035125ΔpCMY42::pCMY42\textsubscript{005008} | 0.64 ± 0.08 | 2.50 ± 0.62 |
| 035125ΔpCMY42::pCMY42\textsubscript{005008R1} | 6.02 ± 1.68 | 16.76 ± 3.11 |
| 035125ΔpCMY42::pCMY42\textsubscript{005008R2} | 6.02 ± 1.50 | 14.84 ± 1.47 |

\textsuperscript{a}The plasmid copy number refers to the ratio of pCMY42 plasmid copies per chromosome for each strain. The plasmid copy number of 035125ΔpCMY42::pCMY42\textsubscript{035125} is 2.37 ± 0.35.
the *bla*\textsubscript{CMY-42}-carrying plasmid (pCMY42\_005008). pCMY42\_005008 is a 68,106-bp IncI plasmid, significantly larger than the 34,321-bp pCMY42\_035125 (Fig. 3), but the two plasmids have the same IncI replicon sequence. By qRT-PCR, we found that *bla*\textsubscript{CMY-42} expression in 005008 was 0.64-fold higher than that in 035125 (Table 2), which could explain the discrepancy in ATM-AVI MIC. We then performed mutagenesis experiments for 005008 and obtained two ATM-AVI-resistant (MIC, 64/4 mg/liter; Table 1) mutants, 005008\textsubscript{R1} and 005008\textsubscript{R2}. We performed genome sequencing for both and found that the two mutants were different from the parental strain by a single SNP at different positions in the IncI \textit{inc} gene, A29G for 005008\textsubscript{R1} and T32A for 005008\textsubscript{R2} (Fig. 2), compared with the parental strain 005008. The *bla*\textsubscript{CMY-42}-carrying plasmids of 005008, 005008\textsubscript{R1}, and 005008\textsubscript{R2} were introduced into 0035125\textsubscript{ΔpCMY42} by electroporation. The presence of either A29G or T32A mutation led to a 16-fold increase in ATM-AVI MIC.

---

**FIG 3** Comparison between pCMY42\_005008 (68,106 bp) and pCMY42\_035125 (34,321 bp). The figure was generated using BRIG (36), with GC skew and GC content being shown. Shown are \textit{inc} and \textit{repZ} of the IncI replicon, *bla*\textsubscript{CMY-42}. Compared with pCMY42\_005008, pCMY42\_035125 lacks a 20-kb conjugative region containing multiple \textit{pil} genes (\textit{pilL} to \textit{pilV}) encoding the IncI thin pili (43) and several genes involved in the biogenesis of the IncI thick pili, such as \textit{traE}, \textit{traF}, and \textit{traG} (44). pCMY42\_005008 also lacks many \textit{tra} genes encoding the IncI thick pili, such as \textit{traI}, \textit{traX}, and \textit{traY} (44), compared with the well-characterized IncI\textsubscript{y} reference plasmid R621a (GenBank accession no. AP011954). Other genes shown here include \textit{psi}\textsubscript{A}-\textit{psi}\textsubscript{B} (encoding plasmid SOS inhibition), \textit{parM} (involved in plasmid partition), and \textit{trb} genes (also involved in conjugative transfer).
(64/4 versus 4/4 mg/liter; Table 1). qRT-PCR revealed that \( \text{bla}_{\text{CMY-42}} \) expression in 005008R1 and 05008R2 was 9.4-fold higher than that in 005008 and 6.0-fold higher than that in 035125\(\Delta\)pCMY42::pCMY42_035125 (Table 2). Correspondingly, the \( \text{bla}_{\text{CMY-42}} \)-carrying plasmid copy number increased from 2.50 per chromosome in 005008 to 16.76 in 005008R1 and 14.84 in 005008R2 (Table 2). Of note, the impact seen for CAZ-AVI was the same as that for ATM-AVI (Table 2).

**DISCUSSION**

ATM mainly binds to PBP3 to achieve its antibacterial effect (20). The four-amino-acid (YRIK, YRIN, or YRIP) insertion is located in the tight turn between the \( \beta_2b–\beta_2c \) sheets adjacent to the \( \beta \)-lactam binding pocket (13). Such an insertion would disrupt the tight \( \beta \)-sheet and, therefore, would hinder the efficient binding of \( \beta \)-lactams such as ATM and CAZ (13). In a previous study (13), strains with the YRIK insertion have been shown to have a slightly higher ATM-AVI MIC (8 to 16 versus 4 mg/liter) than those with the YRIN insertion. However, such observations were based on strains with a different clonal background. Our analysis shows that the three types of amino acid insertion (YRIK, YRIN, and YRIP) have the same impact on ATM-AVI. This confirms that the location rather than the sequence of the insertion is critical to reduce the affinity to certain \( \beta \)-lactams. The amino acid insertions do not interfere with the essential transpeptidase function of PBP3 (13). Therefore, the insertion in PBP3 alone is inadequate to confer resistance to ATM-AVI.

In the presence of the PBP3 insertion, production of CMY-42 leads to ATM-AVI resistance. Compared to CMY-2, CMY-42 has enhanced activity against ATM. Although AVI can inhibit CMY-42, such inhibition appears to be compromised, as evidenced by the slightly increased ATM-AVI MIC against the strain producing CMY-42 compared to that producing CMY-2 (0.03/4 versus 0.015/4 mg/liter; Table 1) in the absence of the PBP3 insertion. A previous study has found that eight amino acids of AmpC cephalosporinases, i.e., Ser64, Lys67, Gln120, Tyr150, Asn152, Thr316, Lys315, and Asn346 (Ambler's positions), are the key residues to interact with AVI (21). The amino acid substitution in CMY-42 is not one of the eight key residues and, therefore, is unlikely to significantly interfere with the inhibition by AVI. Another previous study exhibited that the amino acid substitution (Val231Gly) in CMY-30, which also occurs at the same position (Ambler’s position 211) as CMY-42 (Val231Ser) compared to CMY-2, leads to enhanced hydrolysis against ATM and CAZ but not against carbapenems (22). This appears to be due to the more remote position of the R1 side chain of ATM and CAZ (both agents share the same R1 side chain in structure) from the amino acid at Ambler’s position 211, which therefore reduces the possibility for steric clashes (22). The additional polar bond between the hydrogen atom of 231Ser and oxygen atom of 232Ser in CMY-42 (Fig. S1) could reduce the interference of atoms at that position (231 from the start codon, Ambler’s position 211) and, therefore, may allow more interaction between the enzyme and the substrate, e.g., ATM and CAZ.

In the replicon of the I-complex family, such as IncI1 and IncI\(\gamma\) plasmids, the antisense regulatory Inc RNA encoded by inc folds into a single stem-loop (23) and binds to RepZ mRNA, transcribing the replication initiation protein RepZ (24). All mutations found in the \( \text{bla}_{\text{CMY-42}} \)-carrying plasmids of 035125, 035148, 005008R1, and 005008R2 are located in the stem-loop region of inc. SNPs in the inc loop region can interfere with the binding of the antisense RNA and RepZ mRNA and, therefore, reduce the ability of inc to inhibit repZ translation, resulting in enhanced Inc plasmid replication and increased plasmid copy number (23, 25). Therefore, the expression of \( \text{bla}_{\text{CMY-42}} \) is enhanced in these Inc\(\gamma\) plasmids with inc mutations, as demonstrated in a previous study, in which the increased expression of \( \text{bla}_{\text{CMY-2}} \) in an IncI1 plasmid due to inc mutations led to resistance to piperacillin-tazobactam (19). The hexanucleotides TTGGCG (positions 31 to 36) in the inc loop region are interaction sites with RepZ mRNA (23, 25). The mutations seen in 035125 (G38T), 035148 (C30A), 005008R1 (A29G), and 005008R2 (T32A) are all located adjacent to or in the TTGGCG hexanucleotides (Fig. 2) but led to varied levels of reduced inhibition of repZ. This suggests that mutations in
the loop region at different locations or with different nucleotides confer differential impacts on plasmid copy number control, which warrants further studies.

The reduced affinity of PBP3 to ATM increases the exposure of the agent to CMY-42, a class C β-lactamase. Unlike β-lactam-type β-lactamase inhibitors, such as clavulanic acid, sulbactam, or tazobactam, the inhibition of β-lactamases by AVI is reversible by recycylation (21, 26) and usually does not result in hydrolysis (21). This suggests that even in the presence of AVI, some free forms of CMY-42 enzymes still exist and, therefore, are available to attack ATM. CMY-42 has strong hydrolyzing activity against ATM, and the increased amount of the enzyme resulting from the increased copy number of the \( \text{bla}_{\text{CMY-42}} \)-carrying plasmid would likely be sufficient to significantly reduce the amount of ATM to reach its target, PBP3, and then realizes resistance to ATM-AVI. This is also supported by the fact that an increase of AVI to 8 mg/liter largely restores the susceptibility of ATM, as shown in Table 1. It is worth pointing out that despite the present study focusing on ATM-AVI, the above-described mechanisms, including PBP3 insertion and the enhanced expression of \( \text{bla}_{\text{CMY-42}} \), have impacts on CAZ-AVI equal to those of ATM-AVI, as demonstrated in Results.

In conclusion, the concerted combinatorial effect of three elements, i.e., target alteration, hydrolyzing enzyme, and plasmid expression, is able to overcome the protection of AVI for ATM and CAZ, leading to clinically relevant resistance in \( E. \text{coli} \).

MATERIALS AND METHODS

Strains and in vitro susceptibility testing. \( E. \text{coli} \) isolates 035125, 035123, and 035148 (all of sequence type 410 [ST410]) were recovered from hospital sewage of West China Hospital in March 2018. Carbapenem-resistant \( E. \text{coli} \) (CREC) clinical strain 005008 (ST3835) was recovered from ascites of an intensive care unit patient in 2014 (17), while CREC strain 020066 (ST6823) was recovered from urine of a hospitalized patient in 2017 (18).

A 200-μl sample of hospital sewage was collected from the influx mainstream of the wastewater treatment plant at West China Hospital in November 2017 and then was streaked onto a chromogenic agar plate (CHROMagar enterobacteria; CHROMagar; Paris, France) containing 8/4 mg/liter ATM-AVI and 64 mg/liter linezolid. The addition of linezolid was to inhibit the growth of Gram-positive bacteria. The plate was then incubated at 37°C overnight. The colonies were picked and streaked on the same types of plates as those described above for purification. Preliminary species identification was based on the matrix-assisted laser desorption ionization time-of-flight mass spectrum (MALDI-TOF) (Bruker; Billerica, MA).

MICs of amikacin, ATM, ATM-AVI, CAZ, CAZ-AVI, ciprofloxacin, colistin, imipenem, meropenem, piperacillin-tazobactam, tigecycline, and trimethoprim-sulfamethoxazole were determined using the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI) (27). In addition, to test whether increased concentrations of AVI could enhance the protection for ATM and CAZ, MICs of ATM and CAZ were also determined in the presence of 8 mg/liter AVI. The breakpoints of ATM defined by the CLSI were applied for ATM-AVI and ATM-AVI (8 mg/liter AVI), and those of CAZ-AVI were also applied for CAZ-AVI (8 mg/liter AVI). Of note, throughout the manuscript, AVI in ATM-AVI and CAZ-AVI is at 4 mg/liter unless indicated otherwise. As there are no breakpoints of tigecycline from the CLSI, those defined by EUCAST (http://www.eucast.org/) were applied.

Whole-genome sequencing and analysis. Genomic DNA of 035125, 035123, 035148, 005008, 005008R1, and 005008R2 was extracted using the QIAamp DNA minikit (Qiagen, Hilden, Germany), and whole-genome sequencing was performed using a HiSeq X10 platform (Illumina, San Diego, CA, USA). Sequence reads were subjected to strict quality control using Cutadapt v2.5 (28) and BBTools v38.68 (https://sourceforge.net/projects/bbmap/) until no further improvements were observed on the reads. Trimmed reads were downsampled to 100x depth if exceeding this threshold and then assembled into draft genomes with a minimum contig size of 200 bp using SPAdes v3.14.1 (29) invoked in Shovill v1.0.9 (https://github.com/tseemann/shovill) under careful mode.

035125, 035123, 035148, and 005008 were also sequenced using a long-read MinION sequencer (Nanopore, Oxford, UK). Genomic DNA was prepared using phenol-chloroform to minimize fragmented DNA. The output long reads were base called and demultiplexed using Guppy v3.2.4 (https://nanoporetech.com/nanopore-sequencing-data-analysis). Short Illumina reads and long MinION reads were subjected to de novo hybrid assembly using Unicycler v0.4.8 (30) under the conservative mode for improving accuracy. Complete circular contigs were then corrected and polished using Pilon v1.22 (31), in addition to the integrated polishing steps in Unicycle. A quality check was performed on the assembled genomes using CheckM v1.0.18 (32) to determine the existence of contamination. Genomes were annotated using Prokka v1.14.3 (33). ST was determined by querying the multilocus sequence typing database of \( E. \text{coli} \) (http://enterobase.warwick.ac.uk/species/index/ecoli). Antimicrobial resistance genes were predicted using AMRFinderPlus v3.2.3 (34). Plasmid replicons were identified using ABRicate v0.9.8 (https://github.com/tseemann/abricate) with PlasmidFinder (35). The comparison between the \( \text{bla}_{\text{CMY-42}} \)-carrying plasmid of 035125 and that of 005008 was performed using BRIG (36) with default settings.


TABLE 3 Primers used in this study

| Primer                         | Sequence (5’–3’)       | Size (bp) | Target gene or region |
|-------------------------------|------------------------|-----------|-----------------------|
| pCMY42-Incl-R                 | GCATTCAAGAGAGATGCCAT   | 141       | Incl replicon         |
| pCMY42-Incl-L                 | CCGCAGTTCTGCTGAGG      | 148       | bla<sub>CMY-42</sub>  |
| pCMY42-cmy42-R                | CTGGGAGATGGCTGAATG     | 2,100     | bla<sub>CMY-42</sub>  |
| pCMY42-cmy42-L                | AGTGGAGGCGCTTTGATGCA   | 2,218     | bla<sub>CMY-2</sub>   |
| pET-15-1Nhl-up                | AATTGAGCCCAACAGTATGCTGCATT | 1,779   | pbp3                  |
| pET-cmy42-BamHI-dw            | AAAGGATCCAAAGGGGACAAAATTATCGTG | 125     | bla<sub>CMY-42</sub>  |
| pET-cmy2-BamHI-dw             | AAAAGGATCCAAAGGGGACAAAATTATCGTG | 1,40     | repZ                   |
| pBCSK-pbp3-EcoRI-up           | AGGGAATCTGAAAGACGCGGACAAAG | 135     | recA                   |
| cmy42/cmy2-qpcr-R             | TCGCAATAACACCCCCAGCTG  | 125       | bla<sub>CMY-42</sub>/bla<sub>CMY-2</sub> |
| rep2-qpcr-R                   | CTGGGAGATGGCTGAATG     | 2,100     | bla<sub>CMY-42</sub>  |
| rep2-qpcr-L                   | CTGGGAGATGGCTGAATG     | 2,218     | bla<sub>CMY-2</sub>   |
| recA-qpcr-L                   | GAAAGGGATCCAAAGGGGACAAAATTATCGTG | 125     | bla<sub>CMY-42</sub>  |
| recA-qpcr-R                   | GAAAGGGATCCAAAGGGGACAAAATTATCGTG | 125     | bla<sub>CMY-42</sub>/bla<sub>CMY-2</sub> |

*Restriction sites are underlined.

Reads of 035123, 035125, and 035148 were aligned using Snippy v4.4.5 (https://github.com/tseemann/snippy) with default settings. Recombination was detected using Gubbins v2.3.4 (37) with a maximum of 100 iterations for convergence under the GTRGAMMA model. A pair-wise core SNP distance excluding SNPs residing in the recombination regions was calculated using snp-dists v0.6.3 (https://github.com/tseemann/snp-dists). The same procedure was also used for SNP calling between 005008 and its mutants.

Curation of plasmids by SDS treatment. To obtain a bla<sub>CMY-42</sub>-carrying plasmid-cured variant of strain 035125, the strain was incubated in 10 ml freshuria-Bertani (LB) broth containing 0.02% SDS at 37°C overnight (38). The culture was diluted 10<sup>–3</sup> in fresh LB broth, and a 100-μl aliquot was plated onto an LB agar plate. The bacterial colonies were transferred using sterilized sticks onto an LB agar plate containing 50 mg/liter amikacin. The presence of E. coli strain J53 AizR as the recipient at both 25 and 37°C as described previously (39). Potential transformants were selected on LB agar plates containing 50 mg/liter chloramphenicol. The presence of the cloned fragments was confirmed by PCR using generic primers M13-20/M13 with reverse binding to the cloning region of pBC SK and subsequent Sanger sequencing.

The –10 and –35 boxes of the promoter of bla<sub>CMY-2</sub> and bla<sub>CMY-42</sub> were predicted using the online tool BPRoM (http://www.softberry.com/). The complete coding sequences of bla<sub>CMY-2</sub> and bla<sub>CMY-42</sub> and their promoter regions were amplified from strains 020147 (E. coli ST410) (18) and 035125, respectively, using PrimeSTAR Max DNA polymerase (primers are in Table 3; TaKaRa; Dalian, China). PCR amplicons and the pBC SK vector (Stratagene, La Jolla, CA, USA) were digested using BamHI and NheI and then were ligated using T4 ligase (New England Biolabs) to construct p8C SK-pbp3, pBP3, pBC SK-pbp3, BL21, which was transformed into E. coli BL21 by chemical transformation. Potential transformants were selected on LB agar plates containing 50 mg/liter chloramphenicol. The presence of the cloned fragments was confirmed by PCR using generic primers M13-20/M13 with reverse binding to the cloning region of pBC SK and subsequent Sanger sequencing.

Conjugation and electroporation experiments. Conjugation experiments were carried out in broth and on filters with the azide-resistant E. coli strain J53 AizR as the recipient at both 25 and 37°C as described previously (39). Potential transconjugants were selected on LB agar plates containing 16 mg/liter ATM. Plasmids were prepared using alkaline lysis (40). Electroporation was performed using the protocol for E. coli (41) using a Gene Pulser (Bio-Rad, Hercules, CA, USA). Transforms were selected on LB agar plates containing 16 mg/liter ATM, and the presence of bla<sub>CMY-42</sub> in transformants was confirmed by PCR and subsequent Sanger sequencing of amplicons.

qRT-PCR. Overnight cultures of 035125, 035123, 035148, 005008, 005008R1, and 005008R2 were inoculated (1:100 dilution) into LB medium and were incubated at 37°C with vigorous shaking. At an optical density at 600 nm of 0.6, cell pellets were harvested by centrifugation, and RNA was extracted using the bacterial RNA kit (Omega Bio-Tek, Norcross, GA) with the treatment of on-membrane DNase I digestion to remove DNA contamination. Reverse transcription of RNA to cDNA was performed using a
PrimeScrip RT reagent kit (TaKaRa). Gene-specific primers were designed using the Primer3 software (http://frodo.wi.mit.edu/), qRT-PCR of bla\textsubscript{CMY-42} and repZ were carried out using LightCycler 96 (Roche, Basel, Switzerland) with FastStart essential DNA green master (Roche) and self-designed primers (Table 3). The housekeeping gene recA was used as an internal control for the quantification of relative gene expression. For each strain, three independent cultures were used to extract RNA as three biological replicates, and for each RNA sample, the whole process of qRT-PCR was repeated in triplicate as technical replicates. Relative transcript levels were calculated using the $2^{-\Delta\Delta C_T}$ formula based on the mean values.

**In vitro resistance mutation assay.** Strain 005008 was consecutively streaked on LB agar plates containing incremental concentrations of ATM-AVI from 2/4 to 32/4mg/liter to obtain resistance mutants. Two such mutants, 005008R1 and 005008R2, were subjected to whole-genome sequencing.

**Replicates.** Relative transcript levels were calculated using the $2^{-\Delta\Delta C_T}$ formula for repZ compared with that for recA based on the mean values.

**Data availability.** Complete genomes of strains 035125, 035123, 035148, and 005008 have been deposited in GenBank under accession numbers CP029365 to CP029369 and CP029365 to CP029369. Draft genomes of 005008R1 and 005008R2 have been deposited in GenBank under accession numbers JACGF000000000 and JACGF00000000, respectively.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1,** PDF file, 0.7 MB.

**FIG S2,** PDF file, 0.02 MB.

**FIG S3,** PDF file, 0.3 MB.

**TABLE S1,** DOCX file, 0.02 MB.

**ACKNOWLEDGMENTS**

This work was supported by grants from the National Natural Science Foundation of China (project no. 81861138055 and 81661130159), a grant (project no. ZYYC08006) from West China Hospital of Sichuan University, and the Newton Advanced Fellowship, Royal Society, UK (NA150363).

We have no conflict of interest to declare.

**REFERENCES**

1. Schrader SM, Vauboishej J, Nathan C. 2020. Biology of antimicrobial resistance and approaches to combat it. Sci Transl Med 12:eaaz6992. https://doi.org/10.1126/scitransmed.aaz6992.

2. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vliegeh E, Haro GL, Gould IM, Goossens H, Greco C, So AD, Bignell M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Cao PN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Gniadkowski M, Livermore DM, Miriagou V, Rossolini GM, Samuelsen O, Seifert H, Woodford N, Nordmann P, European Network on Carbapenemases. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413–431. https://doi.org/10.1111/j.1469-0691.2012.03821.x.

3. Harbath S, Samore MH. 2005. Antimicrobial resistance determinants and future control. Emerg Infect Dis 11:794–801. https://doi.org/10.3201/eid1106.050167.

4. Schrader SM, Vauboishej J, Nathan C. 2020. Biology of antimicrobial resistance and approaches to combat it. Sci Transl Med 12:eaaz6992. https://doi.org/10.1126/scitransmed.aaz6992.

5. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vliegeh E, Haro GL, Gould IM, Goossens H, Greco C, So AD, Bignell M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Cao PN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Gniadkowski M, Livermore DM, Miriagou V, Rossolini GM, Samuelsen O, Seifert H, Woodford N, Nordmann P, European Network on Carbapenemases. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413–431. https://doi.org/10.1111/j.1469-0691.2012.03821.x.

6. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791–1798. https://doi.org/10.3201/eid1710.110655.

7. Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen O, Seifert H, Woodford N, Nordmann P, European Network on Carbapenemases. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18:413–431. https://doi.org/10.1111/j.1469-0691.2012.03821.x.

8. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharan S, Dowmuth M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17). J Antimicrob Chemother 75:384–391. https://doi.org/10.1093/jac/dkz456.
| Publication | Authors | Title | Journal | Year |
|------------|---------|-------|---------|------|
| 10. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol 19:589–595. | | Trends Microbiol | 2011 | 10.1016/j.tim.2011.09.005. |
| 11. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009. Characterization of a new metallo-β-lactamase gene, bla<sub>NDM-1</sub>, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–5054. | | Antimicrob Agents Chemother | 2009 | 10.1128/AAC.00774-09. |
| 12. Niu S, Wei J, Zou C, Chavda KD, Lv J, Zhang H, Du H, Tang YW, Pitout JJD, Bonomo RA, Kreiswirth BN, Chen L. 2020. In vitro selection of aztreonam/avibactam resistance in dual-carbenapenem-producing Klebsiella pneumoniae. J Antimicrob Chemother 75:559–565. | | J Antimicrob Chemother | 2020 | 10.1093/jac/dkaa468. |
| 13. Alm RA, Johnstone MR, Lahiri SI. 2015. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBPs3. J Antimicrob Chemother 70:1420–1428. | | J Antimicrob Chemother | 2015 | 10.1093/jac/dku568. |
| 14. Russ D, Glaser F, Shaer Tamar E, Yelin I, Baym M, Kelsic ED, Zampaloni C, Baym M, Kelsic ED, Zampaloni C, | | | | |
| 15. Hentschke M, Kotsakis SD, Wolters M, Heisig P, Miriagou V, Aepfelbacher M. 2011. CMY-42, a novel plasmid-mediated CMY-2 variant AmpC β-lactamase. Microb Drug Resist 17:165–169. | | Microb Drug Resist | 2011 | 10.1098/mdr.2010.0137. |
| 16. Zhang Y, Kashikar A, Brown CA, Denys G, Bush K. 2017. Unusual Escherichia coli PBP 3 insertion sequence identified from a collection of carbapenem-resistant Enterobacteriaceae tested in vitro with a combination of cefazidime, cefetaroline, or aztreonam-avibactam. Antimicrob Agents Chemother 61:e00389-17. | | Antimicrob Agents Chemother | 2017 | 10.1128/AAC.00389-17. |
| 17. Feng Y, Yang P, Xie Y, Wang X, McNally A, Zong Z. 2015. Escherichia coli sequence type 3835 carrying bla<sub>NDM-1</sub>, bla<sub>TEM-19</sub>, bla<sub>CMY-2</sub> and bla<sub>SHV-12</sub>. Sci Rep 5:12275. | | Sci Rep | 2015 | 10.1038/srep12275. |
| 18. Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. 2007. Binding of cefotibiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51: 2621–2624. | | Antimicrob Agents Chemother | 2007 | 10.1128/AAC.00299-07. |
| 19. Lahiri SI, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother 58:5704–5713. | | Antimicrob Agents Chemother | 2014 | 10.1128/AAC.00357-14. |
| 20. Kotsakis SD, Papagiannitsis CC, Tzetele I, Tsouvelakis LS, Miriagou V. 2009. Extended-spectrum properties of CMY-30, a Val121Gly mutant of CMY-2 cephalosporinase. Antimicrob Agents Chemother 53:3520–3523. | | Antimicrob Agents Chemother | 2009 | 10.1128/AAC.00219-09. |
| 21. Asano K, Mizobuchi K. 1998. Copy number control and resistance to a β-lactam and resistance to a β-lactamase inhibitor. Proc Natl Acad Sci USA 95:11663–11668. | | Proc Natl Acad Sci USA | 1998 | 10.1073/pnas.95.22.11663. |
| 22. Asano K. 2016. Resistance to Aztreonam-Avibactam in Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: a covalent, reversible, non-β-lactam β-lactamase inhibitor. Plasmid 75:97–112. | | Plasmid | 2016 | 10.1016/j.plasmid.2014.12.005. |
| 23. Asano K, Niimi T, Yokoyama S, Mizobuchi K. 1998. Structural basis for binding of the plasmid ColIb-P9 antisense Inc RNA to its target RNA with the 5′-UUUGGC-3′ motif in the loop sequence. J Biol Chem 273: 11826–11838. | | J Biol Chem | 1998 | 10.1074/jbc.273.19.11826. |
| 24. Ehrmann DE, Jach H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. | | Proc Natl Acad Sci U S A | 2012 | 10.1073/pnas.120573109. |
| 25. Praszkier J, Pittard AJ. 2005. Control of replication in I-complex plasmids. PLoS Comput Biol 19:455–477. | | PLoS Comput Biol | 2005 | 10.1128/cmb.2012.0021. |
| 26. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005955. | | PLoS Comput Biol | 2017 | 10.1371/journal.pcbi.1005955. |
| 27. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2068–2069. | | Bioinformatics | 2014 | 10.1093/bioinformatics/btu153. |
| 28. Carattoli A, Zankari E, Garcia-Fernandez A, Voldby Larsen S, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother 58:3983–3993. | | Antimicrob Agents Chemother | 2014 | 10.1128/AAC.00483-19. |
| 29. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005955. | | PLoS Comput Biol | 2017 | 10.1371/journal.pcbi.1005955. |
| 30. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005955. | | PLoS Comput Biol | 2017 | 10.1371/journal.pcbi.1005955. |
| 31. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDM carbapenemases. Trends Microbiol 19:589–595. | | Trends Microbiol | 2011 | 10.1016/j.tim.2011.09.005. |
| 32. Asano K, Niimi T, Yokoyama S, Mizobuchi K. 1998. Structural basis for binding of the plasmid ColIb-P9 antisense Inc RNA to its target RNA with the 5′-UUUGGC-3′ motif in the loop sequence. J Biol Chem 273: 11826–11838. | | J Biol Chem | 1998 | 10.1074/jbc.273.19.11826. |
| 33. Ehrmann DE, Jach H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663–11668. | | Proc Natl Acad Sci U S A | 2012 | 10.1073/pnas.120573109. |
| 34. CLSI. 2019. Performance standards for antimicrobial susceptibility testing: 30th informational supplement. M100-S30. Clinical and Laboratory Standards Institute, Wayne, PA. | | CLSI | 2019 | |